Pharmacoeconomic Analysis of Hypertriglyceridemia Treatment at the Medical Institutions

Access this Article

Author(s)

    • 高橋 努 TAKAHASHI Tsutomu
    • 日本大学薬学部薬事管理学ユニット|駿河台日本大学病院 薬剤部 Social and Administrative Pharmacy Science Unit, College of Pharmacy, Nihon University
    • 白神 誠 SHIRAGAMI Makoto
    • 日本大学薬学部薬事管理学ユニット Social and Administrative Pharmacy Science Unit, College of Pharmacy, Nihon University

Abstract

  It has been demonstrated that HMG-CoA reductase inhibitors effectively decrease low density lipoprotein and total cholesterol levels, and presently, HMG-CoA reductase inhibitors are most widely used in hyperlipidemia treatment. On the other hand, it has been demonstrated that fibrate agents decrease triglyceride levels more effectively compared to HMG-CoA reductase inhibitors. A cost-effectiveness study comparing fenofibrate, a fibrate agent, and atorvastatin was therefore conducted in hypertriglyceridemia patients. Referring to an analytical method published in the UK, the percentage of patients received fenofibrate and atorvastatin treatments at each dose level was estimated from prescription records at the medical institutions investigated. Changes in the total cholesterol and triglyceride values after the drug administration were investigated examining published reports. Based on the said data, the treatment effectiveness was measured by the percentage of patients who achieved the target lipid levels. The treatment costs were estimated based on the number of patients investigated and reimbursement prices of the drugs. The incremental cost-effectiveness ratio of fenofibrate in decreasing triglyceride levels was dominant over atorvastatin. The incremental cost-effectiveness ratio of atorvastatin in decreasing low density lipoprotein cholesterol levels was JPY 69911. This provides a model for choosing drug treatments that reflects clinical practices at medical institutions by substituting figures for individual cases.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 128(12), 1783-1789, 2008-12-01

    The Pharmaceutical Society of Japan

References:  13

Codes

  • NII Article ID (NAID)
    110007005960
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    00316903
  • NDL Article ID
    9732795
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-411
  • Data Source
    CJP  NDL  NII-ELS  J-STAGE 
Page Top